• Skip to main content
  • Skip to header right navigation
  • Skip to site footer
  • About Us
  • Contact Us
  • Billing Portal
SPRINT® PNS System

SPR Therapeutics

SPRINT PNS System

  • Product
  • For Physicians
    • Clinical Outcomes & References
    • Implant Procedure Videos
    • Video Resources
    • SPRcare Reimbursement
    • Important Safety Information
    • MRI Safety Information
    • Promotional Marketing Toolkit
  • For Patients
    • Patient Stories
    • Patient Resources
    • Recursos para pacientes
    • MicroLead™ Safety
    • MRI Safety Information
  • Clinical Trials
  • News & Events
    • News
    • Events
    • Press Room
  • Careers

INVEST IN NEW PAINKILLER TECHNOLOGY “DISRUPTIFYING” THE $25 BILLION OPIOID INDUSTRY

August 29, 2019

If you’ve ever dealt with pain, you know there aren’t a lot of options for you.

In fact, the treatment hasn’t changed much since the ancient Greeks first discovered the bark from willow trees contains a natural analgesic — salicin, a close chemical cousin to aspirin.

But major changes are coming — and are long overdue.

A handful of startups and biotech companies are developing safer alternatives to pain pills in the face of the growing opioid crisis.

These innovations threaten to shake Big Pharma’s hold on the $25 billion global opioid market, which is poised for massive Disruptification.

Among these innovations are medicine-delivering implants, microscopic robots, high-tech skin patches and electrical-stimulation circuits — some of which are just getting the green light from regulators.

These nonaddictive, new-world biotech alternatives are not only great news for the 3 in 10 Americans who suffer with chronic pain, but they also provide a tremendous investment opportunity.

It’s exactly what we look for here at Bold Profits. In fact, we’ve found four companies that are leading the new pain revolution. One company’s stock is already up nearly 214% since we recommended it.

And today, I’ll share two additional ways to play the tech drivers behind these innovations. But first, let’s take a look at what those drivers are.

PROFIT FROM THE END OF THE OPIOID EPIDEMIC

Pain is big business in this country and around the world.

About 30% of Americans suffer from chronic or severe pain, according to the Centers for Disease Control and Prevention.

The global pain management market is a $45 billion industry and growing.

But painkillers are becoming another symbol of our old-world, “one size fits all” medical system that is giving way to more effective new-world, biotech-based “precision medicine” techniques.

One example emerged just this week in a landmark opioid lawsuit. On Monday, an Oklahoma judge ordered Johnson & Johnson to give $572 million to the state in the first-ever court ruling to hold a company responsible for the opioid crisis. If the opioid industry isn’t feeling it, they will soon.

So, drug companies are on the run — from lawsuits like these and regulators who are tightening laws on pain pill makers. As a result, biotech companies, startups and research institutions are stepping into the gap with high-tech fixes that I believe offer the best prospect for combating the opioid epidemic and making investors a bundle.

Here are just a few examples:

  • Researchers at the Swiss Federal Institute of Technology Lausanne in Switzerland have created a remote-controlled robotic implant that can release pain medication to a specific area, reducing the chance of addiction. The implant — 25 times smaller than the period at the end of this sentence — is now used to help patients fitted with an orthopedic prosthetic.
  • Engineers at the Massachusetts Institute of Technology have developed a minirobot that folds up into a pill. Once ingested, it’s guided to a particular place inside the body by external magnetic fields and unfolds to release medication.
  • Cleveland’s SPR Therapeutics has contracted with the U.S. Department of Defense to provide veterans a nonopioid pain relief therapy called the Sprint Peripheral Nerve Stimulation System. A similar device, produced by a Florida company called Stimwave, was recently approved by the U.S. Food and Drug Administration and offers long-term pain relief.

On top of that, the power of the internet is fueling the painkiller revolution.

For example, Chicago-based startup Triggr Health and Denver’s RxAssurance make smartphone apps that help identify the best therapy and doctors for those fighting addiction.

Major breakthroughs in semiconductors and chip technology are starting to make it possible to end the epidemic.

These advances have created amazingly powerful and tiny new breeds of microchips at the center of some of the most exciting new painkiller innovations affecting the opioid industry.

GRAB TRIPLE-DIGIT GAINS AND BEAT THE BROAD MARKET 2-TO-1

There are several ways you can profit from this new biotech pain-treatment trend.

One way is to put your money into stocks of companies on the forefront of biotech, semiconductors, medical technology and precision medicine.

For example, our Profits Unlimited portfolio features a semiconductor company whose stock is up nearly 214% since it was recommended. And our True Momentum service includes three biotech firms or precision medicine leaders whose stocks have soared almost 204%, 126% and 67%.

Another way is to invest in an exchange-traded fund (ETF) that features medical device manufacturers and robotics innovators. Two good bets are the Global X Robotics & Artificial Intelligence ETF (Nasdaq: BOTZ) and the iShares U.S. Medical Devices ETF (NYSE: IHI). IHI is up nearly 25% year to date — beating the broad market nearly 2-to-1.

Until next time…

To your health and wealth,

Nick Tate
Senior Editorial Manager, Banyan Hill Publishing

Read the full article at Bayanhill.com.

Share this post:

Share on Twitter Share on Facebook Share on LinkedIn Share on SMS Share on Email
Category: News
Previous Post:SPR Therapeutics’ SPRINT Peripheral Nerve Stimulation System Significantly Reduces Opioid Use in Patients with Low Back Pain, Interim Data Show
Next Post:NANS Summer Series

Sidebar

Archives

Recent News

Dr. Samir Sheth discusses how the SPRINT® PNS System has impacted his approach to treating patients with chronic head and neck pain

SPR Therapeutics Debuts Occipital Nerve Stimulation Data at ASRA 2022

A Discussion on Pain Management Options for Patients with Breast Cancer with Dr. Amitabh Gulati

Real-World Retrospective Review of Axial Neck Pain Relief Following Peripheral Nerve Stimulation of Cervical Medial Branch Nerves

Pain Medicine News Features SPRINT® PNS System Real-World Survey Outcomes

Tags

60-day percutaneous PNS acute pain Back Pain back pain treatment cancer pain chronic back pain Chronic Pain clinical study Dr. Mehul Desai drug-free EY award hip pain low back pain medial branch Neuromodulation Non-opioid oncological pain opioid alternative Pain pain appointment pain physician pain relief pain treatment Patients Patient Story peripheral nerve stimulation permanent PNS implant phantom limb pain PNS PNS training post-amputation pain Press release radiofrequency ablation recondition CNS reduced opioids research Research study residual limb pain RFA Shoulder Pain SPRINT PNS SPRINT PNS System temporary pns Training lab webinar
SPRINT® PNS System

22901 Millcreek Blvd, Suite 500
Cleveland, OH 44122
(844) 378-9108 Phone
(216) 803-0777 Fax

Top Work Places 2022

Quick Links

  • Product
  • For Physicians
  • For Patients
  • Clinical Trials
  • News & Events
  • Careers
  • About Us
  • Contact Us

Legal Links

  • Privacy Statement
  • Terms of Use
  • CPRA Requests
  • Important Safety Information
  • Compliance
  • FCOI Policy
  • Product Terms & Conditions
  • Patent Information

Recent News Headlines

Dr. Samir Sheth discusses how the SPRINT® PNS System has impacted his approach to treating patients with chronic head and neck pain

NANS 26th Annual Meeting – Las Vegas, NV

Sprint Regional Lab – Jacksonville

Sprint Regional Lab – Chicago

The SPRINT PNS System is indicated for up to 60 days for: (i) Symptomatic relief of chronic, intractable pain, post-surgical and post-traumatic acute pain; (ii) Symptomatic relief of post-traumatic pain; and (iii) Symptomatic relief of post-operative pain. The SPRINT PNS System is not intended to treat pain in the region innervated by the cranial and facial nerves. Physicians should use their best judgment when deciding when to use the SPRINT PNS System. For more information see the SPRINT PNS System IFU. Most common adverse events are skin irritation and erythema. Results may vary. Rx only.

View References for support of all claims.

The SPRINT® PNS System, MicroLead™, OnePass Introducer™, Rethink Your Pain Strategy™, Outsmart Pain™, Sustained Pain Relief Starts Here™, Life. Get Back to It.™ and SPR® are registered or common law trademarks of SPR Therapeutics, Inc.


Copyright © 2023 SPR Therapeutics. All Rights Reserved.

This website is intended only for US and Canadian residents 18 years of age and older. By clicking “Accept”, you consent to the use of ALL the cookies.
Cookie settingsACCEPT
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Others
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
Save & Accept
Powered by CookieYes Logo